Clinical Analysis: 4-Day-Old Neonate with Jaundice, Hepatomegaly & Petechiae

1. Presumptive Diagnosis (PS)

• Neonatal cholestasis / congenital hepatitis with conjugated hyperbilirubinemia
• Complicated by hemolytic anemia

2. Differential Diagnoses (Diff DS)

1. Congenital CMV — most common TORCH infection causing neonatal cholestasis + petechiae + SGA
2. Congenital Toxoplasmosis — similar presentation; classic triad: chorioretinitis, hydrocephalus, intracranial calcifications
3. Congenital Rubella — cataracts, cardiac defects, deafness + purpura (now rare with vaccination)
4. Congenital Syphilis — can cause hepatitis, petechiae, bone lesions
5. Congenital Hepatitis B — maternal transmission; cholestatic jaundice
6. Biliary Atresia — progressive conjugated jaundice, acholic stools, hepatomegaly; NO petechiae, birth weight usually normal; spleen eventually enlarges; must be excluded urgently (Kasai procedure time-sensitive)
7. ABO / Rh Hemolytic Disease of Newborn — typically unconjugated hyperbilirubinemia, positive Coombs; does NOT cause acholic stools or bile pigmenturia; jaundice usually <24 h of life
8. Neonatal Sepsis / bacterial infection — can cause cholestasis + thrombocytopenia (petechiae)
9. Galactosemia / metabolic liver disease — rare, needs urine reducing substances, galactose-1-phosphate uridyltransferase assay
10. Alpha-1 antitrypsin deficiency — chronic neonatal cholestasis

3. Laboratory Examination (Labor. Examination)

4. Treatment & Prophylaxis

Immediate General Measures

• IV access, fluid/electrolyte support, correction of anemia (Hb 100 g/L — monitor closely; transfuse if Hb <80 g/L or symptomatic)
• Nutritional support: NG feeds if tolerating poorly; MCT-enriched formula (better absorbed in cholestasis)
• Fat-soluble vitamin supplementation (A, D, E, K) — reduced absorption in cholestasis
• Vitamin K 1 mg IM if not yet given (coagulopathy risk)

Phototherapy

• For the unconjugated component (indirect bilirubin 136 µmol/L = ~7.9 mg/dL): initiate intensive phototherapy per AAP guidelines
• Total bilirubin 204 µmol/L (~12 mg/dL) — assess against AAP nomogram for gestational age/risk category
• Monitor bilirubin every 4–6 hours during phototherapy
• Exchange transfusion if TSB continues to rise above exchange threshold despite intensive phototherapy (especially with hemolytic disease) — Rosen's Emergency Medicine

Specific Treatment (if CMV confirmed)

• Valganciclovir (oral, 16 mg/kg twice daily × 6 months) — standard of care for symptomatic congenital CMV with CNS involvement; improves neurodevelopmental and audiologic outcomes
• If CNS involvement confirmed → 6-month course; otherwise discuss risk/benefit

If Biliary Atresia cannot be excluded

• Urgent hepatobiliary workup (USS + HIDA scan)
• If confirmed: Kasai portoenterostomy — must be performed before 60 days of age for best outcome

If Sepsis/Bacterial Infection suspected

• Empiric broad-spectrum antibiotics: Ampicillin + Gentamicin (or Ampicillin + Cefotaxime for meningitis coverage)

Prophylaxis (Pufilac = Prophylaxis)

• Maternal CMV screening in future pregnancies; hygiene counseling (hand-washing, avoid saliva contact)
• Rubella vaccination of mother (post-partum) if not immune
• Hepatitis B: If HBsAg-positive mother → neonate should have received HBIg + HBV vaccine within 12 hours of birth; verify and catch up if missed
• Syphilis: If confirmed, Penicillin G 100,000–150,000 U/kg/day IV × 10 days
• Household and healthcare contact precautions for CMV-excreting infant (urine is infectious)
• Follow-up: Serial liver function tests, ophthalmology, audiology, neurodevelopmental assessment at 6, 12, 24 months

Summary Table